Antifibrotic therapy in MASLD: fibrosis reversal and HCC prevention
Metabolic dysfunction-associated steatotic liver disease/ metabolic dysfunction-associated steatohepatitis (MASLD/MASH) has become a leading cause of advanced chronic liver disease and hepatocellular carcinoma (HCC). Among all histological features, liver fibrosis is the strongest predictor of liver-related outcomes an...